Due to a production error, several author names were incorrectly written. The names of Omar S. Al-Odat, Robert J. Chitren, Weam O. Elbezanti, Sandeep K. Srivastava, Subash C. Jonnalagadda, and Bharat B. Aggarwal had their initials mistakenly omitted.
The publisher apologizes for this mistake.
Summary
Keywords
multiple myeloma, drug resistant, Mcl-1, Bcl-2 homology 3 mimetics, apoptosis
Citation
Frontiers Production Office (2021) Erratum: Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma. Front. Pharmacol. 12:758130. doi: 10.3389/fphar.2021.758130
Received
13 August 2021
Accepted
13 August 2021
Published
31 August 2021
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
12 - 2021
Updates
Copyright
© 2021 Frontiers Production Office.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office, pharmacology.production.office@frontiersin.org
This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.